FABP4 and Obesity: Taken together, these studies identify FABP4 as a key molecular driver of CRC aggressiveness and treatment resistance, with consistent evidence supporting its involvement in EMT, lipid metabolism, and therapeutic tolerance, and propose it as a promising therapeutic target for CRC, particularly in obesity-associated and drug-refractory settings.